meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded